My name is Chris Redoble and I'm an independent trader. I've been a heavily involved student of the markets for 7 years. I bought my first stock when I was 12 with my father, Mobil before it became ExxonMobil, then went on to purchase shares of Chevron. I've been fascinated by the markets ever since, and I dreamed of one day working on Wall Street. That dream never came true, and perhaps is even more of a dream now post Financial Crisis 2008. That crisis has not changed my passion for the markets. I currently have a full-time occupation which prevents me from devoting my full attention to the trading day, however I trade throughout the day when I have the time. My long term goals are to have my time fully devoted to the capital markets and journalism. Currently, I am developing a website which will be hybrid style site combining in depth market commentary coupled with real-time news and interviews with other journalists and investment professionals. I will be posting my opinions on the market, with detailed technical analysis charts and visual aids.The site will also contain content relating to "News that Matters" to today's society, with a heavy weighting on financial markets. Stay tuned for details as this will be a very big project for me and I plan for everyone to enjoy what it will have to offer. In the meantime, I hope you enjoy my stock picks, and market commentary. For more detailed commentary, visit my blog http://www.buzzworthyus.com or e-mail me at firstname.lastname@example.org
My career has centered primarily on economics, finance and education. In addition to experience in commercial banking, the securities industry and teaching I pursued advanced research in economics.
I also began to take a long-term interest in the analysis of the dividend-paying capacity of firms. Hence the idea for "dividend support reports" which are intended to examine support for dividends from a longer term historical perspective in a concise format. At present my geographic interest is Asia.
The question arises what kind of analysis is necessary for companies that pay no dividend. For companies that pay no dividends, it may be still be useful to examine whether dividend payments could be supported in the future.
I also have a lifelong interest in languages, art and learning in general, and have been a long-term resident in Asia, having resided in Japan and Chinese Taipei (Taiwan). My book "Japan's Internationalization and Other Essays" gives a perspective of Japan from the experiences of a foreign resident as well as observations on political economy.
I am curious about a variety of industries, economies, economic policy and theory and may consider commenting on these topics from time to time.
The reports are for informational purposes only and are not to be viewed as investment advice or recommendations.
The analytical methodology is not necessarily a constant and may be periodically modified. In addition, while averages may be noted, they may be less meaningful if there are large swings over the period examined. While measures of dispersion such as the standard deviation can be used to capture such movement, I am hesitant to automatically assume that the underlying probability distribution is normal. This concern originates from my experience in finance and economics that insufficient understanding of the underlying probabilistic nature of the data and models can produce significant forecasting errors. A case-in-point might be default probability models that may have erroneously predicted the extent of loan losses in bank portfolios.
I am an active option and etf trader. I do have a real day job which pays me decently, but I enjoy playing the markets.
I normally trade options which are 3 to 6 months in maturities and use strategies such as synthetic long and synthetic shorts.
Retired from engineering/management since 1997. Largely biotech, but some other stocks and real estate investor for over 25 years. Enjoy skiing, sailing, sports. I enjoy the role of Devil's Advocate, so some of what I say may be to provoke discussion, and may not reflect my actual opinion.
I'm currently undergoing treatment for Acute Lymphoblastic Leukemia. I had planed to be skiing now, but sometimes life gets in the way of your plans. While I'm confident of achieving remission, I intend to be very critical of the FDA for the way drug testing is done. I'm strongly in favor of streamlining the clinical trial process, especially when related to drugs for potentially terminal diseases. I am scheduled for stem cell transplantation late this month (4/15).